Sandoz Maintains Lead On Denosumab As It Files With FDA

Firm ‘Among The First’ To Submit US Application For Prolia/Xgeva Biosimilar

 
• By David Wallace
  
Sign outside of FDA's headquarters in White Oak, MD
Sandoz’s BLA for denosumab has been accepted by the FDA • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products